Suspension Granule Composition for Dispersibility and Crystal Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions for treating mitochondrial disorders and neurodegenerative diseases face challenges in achieving optimal dispersibility and stability, particularly in preventing hydrate generation and crystal growth, which affects their efficacy.
Innovation Solution
A pharmaceutical composition comprising a compound represented by formula 1 or its pharmaceutically acceptable salt or solvate, combined with specific binding agents such as cellulose, povidone, and dispersants like light anhydrous silicic acid, to enhance dispersibility and inhibit hydrate formation and crystal growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical compositions are used for treating mitochondrial disorders, then the treatment efficacy can be achieved, but the dispersibility is poor and hydrate generation and crystal growth occur
Solution Approach 1:
The patent introduces a dispersant as an intermediary substance that mediates between the active ingredient and the suspension medium. This dispersant prevents direct contact between the active ingredient and water, thereby inhibiting hydrate generation and crystal growth while maintaining treatment efficacy. The dispersant acts as a protective intermediary layer that ensures both stability and effectiveness.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the pharmaceutical composition by adjusting the concentration of the active ingredient, binding agent, and dispersant. By optimizing these parameters, the composition achieves excellent dispersibility and prevents hydrate formation, while maintaining the therapeutic effectiveness required for treating mitochondrial disorders.
2Reliability
If the concentration of active ingredient is increased to improve effectiveness, then treatment efficacy improves, but hydrate generation and crystal growth are promoted
Solution Approach 1:
The dispersant serves as a protective intermediary that prevents the active ingredient from directly interacting with water, even at high concentrations. This intermediary layer blocks the formation of hydrates and crystals, allowing the active ingredient to maintain high therapeutic concentration without generating harmful hydrate structures or crystals.
Solution Approach 2:
The patent converts the potentially harmful effect of high concentration into a beneficial outcome by using the dispersant to control the distribution of the active ingredient. The high concentration is maintained for effectiveness, but the dispersant ensures uniform distribution that prevents aggregation and hydrate formation, turning a potential harm into a stable, effective formulation.
3Ease of manufacture
If binding agent is added to improve granule formation, then manufacturability improves, but dispersibility may be reduced
Solution Approach 1:
The patent merges the functions of the binding agent and dispersant into a unified formulation where both components work synergistically. The binding agent provides granule formation and structural integrity, while the dispersant ensures uniform distribution and prevents aggregation. This combination achieves both ease of manufacture and excellent dispersibility simultaneously.
Solution Approach 2:
The patent creates a composite material system combining the active ingredient, binding agent, and dispersant in specific proportions. This composite formulation leverages the binding agent for granule formation while the dispersant component prevents aggregation and maintains dispersibility. The composite structure allows both manufacturing convenience and stable dispersion to coexist.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves excellent dispersibility and suppresses hydrate generation and crystal growth, improving the stability and effectiveness of the active ingredients in suspension formulations.
Implementation Method 1
a dispersant; wherein the dispersant is selected from the group consisting of an inorganic salt dispersant, an ether dispersant, a starch dispersant, a cellulose dispersant, and a fatty acid ester salt dispersant
Implementation Method 2
a binding agent; wherein the binding agent comprises a binding agent selected from the group consisting of a cellulose binding agent, a povidone binding agent, a vinyl alcohol binding agent, and a thickening polysaccharide binding agent
Data Source
AI summary
Provided is a granule for suspension, which is a pharmaceutical composition including: a compound represented by formula 1:or a pharmaceutically acceptable salt or solvate thereof, a binding agent; and a dispersant. The binding agent includes a binding agent selected from the group consisting of a cellulose binding agent, a povidone binding agent, a vinyl alcohol binding agent, and a thickening polysaccharide binding agent. The dispersant is selected from the group consisting of an inorganic salt dispersant, an ether dispersant, a starch dispersant, a cellulose dispersant, and a fatty acid ester salt dispersant.